Dexamethasone

[키워드] 350 patient 350 patients 48 hour 48 hours 6-level ordinal scale acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Adrenal cortex hormones Adult patients all-cause mortality rate all-cause mortality rates assessment Berlin criteria caused clinical status clinical trial Control control group Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 - COVID-19 Corticosteroid Corticosteroides Corticosteroids COVID-19 COVID-19-associated ARDS Cuidados críticos days alive defined develop Dexametasona Dexamethasone dexamethasone 10mg IV dexamethasone 20mg intravenous early-onset Effectiveness Eligible patients evaluate evaluated failure followed by group hospitalized patient hospitalized patients Infection intensive care intervention group intravenous Invasive mechanical ventilation less mechanical ventilation mechanical ventilation duration moderate mortality rates multicenter Non-COVID-19 non-COVID-19 acute respiratory distress syndrome objective occur once daily Open-label Ordinal Scale outcome pandemic Patient patients with moderate Pneumonia Pragmatic Primary outcome randomization Randomized randomized trial Randomly receive respiratory respiratory compromise respiratory distress Respiratory distress syndrome Respiratory distress syndrome, adult Síndrome do desconforto respiratório do adulto SARS-CoV-2 SARS-COV-2 infection score secondary Secondary outcomes severe acute respiratory syndrome Coronavirus Spread standard treatment stratified Study design syndrome treated Trial unit discharge ventilator-free day Ventilator-free days Viral Viral pneumonia
[DOI] 10.5935/0103-507X.20200063 PMC 바로가기 [Article Type] Original Article